Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160

J. Pinski, G. Halmos, T. Yano, K. Szepeshazi, Y. Qin, T. Ertl, Andrew V Schally

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Nude mice bearing xenografts of the gastrin-responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin-releasing-peptide(GRP) antagonist (RC-3095), somatostatin analogues RC-160 and SMS 201995, or the combination of RC-3095 and RC- 160. Tumor volumes and weights were reduced signiflcantly to a similar extent by RC-160 and SMS 201-995, administered by daily s.c. injections at a dose of 100 μg/day. Bombesin/GRP antagonist RC-3095, given s.c. at a dose of 20 μg/day, had the greatest inhibitory effect on tumor growth. The combination of RC-3095 with RC- 160 did not further potentiate the suppression of tumor growth. Histologically, the number of mitotic cells decreased significantly in the groups treated with RC- 160 or the combination of RC-3095 with RC- 160. Serum gastrin levels were signiflcantly diminished in all treated groups. Therapy with RC-160 or the combination also signiflcantly decreased levels of serum growth hormone. Receptor assays on tumor membranes showed that bombesin was bound to 2 classes of receptor sites, one with high affinity and low capacity, the other with low affinity and high capacity. Binding sites for epidermal growth factor (EGF) were down-regulated in tumor cells after treatment with RC-3095, RC-160 or the combination of RC-3095 with RC-160. In studies in vitro, both RC-160 and RC-3095 signiflcantly inhibited the proliferation of MKN45 cells in culture as measured by cell number. These data demonstrate, for the first time, that the growth of human gastric cancer in nude mice can be inhibited not only by somatostatin analogues, but also by administration of modern bombesin/GRP antagonists, such as RC-3095

Original languageEnglish
Pages (from-to)574-580
Number of pages7
JournalInternational Journal of Cancer
Volume57
Issue number4
DOIs
StatePublished - Jun 10 1994
Externally publishedYes

Fingerprint

Gastrin-Releasing Peptide
Bombesin
Somatostatin
Heterografts
Nude Mice
Stomach
Carcinoma
Growth
Therapeutics
Gastrins
Tumor Burden
Neoplasms
Cell Count
vapreotide
Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-bombesin (6-14)
Octreotide
Serum
Epidermal Growth Factor
Growth Hormone
Stomach Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. / Pinski, J.; Halmos, G.; Yano, T.; Szepeshazi, K.; Qin, Y.; Ertl, T.; Schally, Andrew V.

In: International Journal of Cancer, Vol. 57, No. 4, 10.06.1994, p. 574-580.

Research output: Contribution to journalArticle

@article{1b5f4861e61c436f8417a5372b7f903e,
title = "Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160",
abstract = "Nude mice bearing xenografts of the gastrin-responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin-releasing-peptide(GRP) antagonist (RC-3095), somatostatin analogues RC-160 and SMS 201995, or the combination of RC-3095 and RC- 160. Tumor volumes and weights were reduced signiflcantly to a similar extent by RC-160 and SMS 201-995, administered by daily s.c. injections at a dose of 100 μg/day. Bombesin/GRP antagonist RC-3095, given s.c. at a dose of 20 μg/day, had the greatest inhibitory effect on tumor growth. The combination of RC-3095 with RC- 160 did not further potentiate the suppression of tumor growth. Histologically, the number of mitotic cells decreased significantly in the groups treated with RC- 160 or the combination of RC-3095 with RC- 160. Serum gastrin levels were signiflcantly diminished in all treated groups. Therapy with RC-160 or the combination also signiflcantly decreased levels of serum growth hormone. Receptor assays on tumor membranes showed that bombesin was bound to 2 classes of receptor sites, one with high affinity and low capacity, the other with low affinity and high capacity. Binding sites for epidermal growth factor (EGF) were down-regulated in tumor cells after treatment with RC-3095, RC-160 or the combination of RC-3095 with RC-160. In studies in vitro, both RC-160 and RC-3095 signiflcantly inhibited the proliferation of MKN45 cells in culture as measured by cell number. These data demonstrate, for the first time, that the growth of human gastric cancer in nude mice can be inhibited not only by somatostatin analogues, but also by administration of modern bombesin/GRP antagonists, such as RC-3095",
author = "J. Pinski and G. Halmos and T. Yano and K. Szepeshazi and Y. Qin and T. Ertl and Schally, {Andrew V}",
year = "1994",
month = "6",
day = "10",
doi = "10.1002/ijc.2910570422",
language = "English",
volume = "57",
pages = "574--580",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160

AU - Pinski, J.

AU - Halmos, G.

AU - Yano, T.

AU - Szepeshazi, K.

AU - Qin, Y.

AU - Ertl, T.

AU - Schally, Andrew V

PY - 1994/6/10

Y1 - 1994/6/10

N2 - Nude mice bearing xenografts of the gastrin-responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin-releasing-peptide(GRP) antagonist (RC-3095), somatostatin analogues RC-160 and SMS 201995, or the combination of RC-3095 and RC- 160. Tumor volumes and weights were reduced signiflcantly to a similar extent by RC-160 and SMS 201-995, administered by daily s.c. injections at a dose of 100 μg/day. Bombesin/GRP antagonist RC-3095, given s.c. at a dose of 20 μg/day, had the greatest inhibitory effect on tumor growth. The combination of RC-3095 with RC- 160 did not further potentiate the suppression of tumor growth. Histologically, the number of mitotic cells decreased significantly in the groups treated with RC- 160 or the combination of RC-3095 with RC- 160. Serum gastrin levels were signiflcantly diminished in all treated groups. Therapy with RC-160 or the combination also signiflcantly decreased levels of serum growth hormone. Receptor assays on tumor membranes showed that bombesin was bound to 2 classes of receptor sites, one with high affinity and low capacity, the other with low affinity and high capacity. Binding sites for epidermal growth factor (EGF) were down-regulated in tumor cells after treatment with RC-3095, RC-160 or the combination of RC-3095 with RC-160. In studies in vitro, both RC-160 and RC-3095 signiflcantly inhibited the proliferation of MKN45 cells in culture as measured by cell number. These data demonstrate, for the first time, that the growth of human gastric cancer in nude mice can be inhibited not only by somatostatin analogues, but also by administration of modern bombesin/GRP antagonists, such as RC-3095

AB - Nude mice bearing xenografts of the gastrin-responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin-releasing-peptide(GRP) antagonist (RC-3095), somatostatin analogues RC-160 and SMS 201995, or the combination of RC-3095 and RC- 160. Tumor volumes and weights were reduced signiflcantly to a similar extent by RC-160 and SMS 201-995, administered by daily s.c. injections at a dose of 100 μg/day. Bombesin/GRP antagonist RC-3095, given s.c. at a dose of 20 μg/day, had the greatest inhibitory effect on tumor growth. The combination of RC-3095 with RC- 160 did not further potentiate the suppression of tumor growth. Histologically, the number of mitotic cells decreased significantly in the groups treated with RC- 160 or the combination of RC-3095 with RC- 160. Serum gastrin levels were signiflcantly diminished in all treated groups. Therapy with RC-160 or the combination also signiflcantly decreased levels of serum growth hormone. Receptor assays on tumor membranes showed that bombesin was bound to 2 classes of receptor sites, one with high affinity and low capacity, the other with low affinity and high capacity. Binding sites for epidermal growth factor (EGF) were down-regulated in tumor cells after treatment with RC-3095, RC-160 or the combination of RC-3095 with RC-160. In studies in vitro, both RC-160 and RC-3095 signiflcantly inhibited the proliferation of MKN45 cells in culture as measured by cell number. These data demonstrate, for the first time, that the growth of human gastric cancer in nude mice can be inhibited not only by somatostatin analogues, but also by administration of modern bombesin/GRP antagonists, such as RC-3095

UR - http://www.scopus.com/inward/record.url?scp=0028199950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028199950&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910570422

DO - 10.1002/ijc.2910570422

M3 - Article

C2 - 7910153

AN - SCOPUS:0028199950

VL - 57

SP - 574

EP - 580

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -